NTRK -rearranged Spindle Cell Neoplasm of the Uterus: An Emerging Entity.

Int J Gynecol PatholOct 6, 2025 (epub)
Case ReportPathology (Anatomic & Clinical)Obstetrics & Gynecology

Haley Corbin, Shikha Malhotra, Kanika Goel et al.

✦ AI-curated · Sources linked

Case in brief

The report describes an NTRK-rearranged spindle cell neoplasm arising in the uterine corpus. Molecular testing identified an NTRK1::TIMP3 fusion. Immunohistochemistry showed diffuse positivity for desmin and progesterone receptor, with negative staining for CD34 and S100. This profile differs from the typical pattern described for these neoplasms, which is CD34- and S100-positive and desmin- and hormone-receptor-negative. The abstract does not provide further clinical presentation, treatment, or outcome details.

What made this case unusual

The uterine corpus location, previously unreported NTRK1::TIMP3 fusion partner, and immunophenotype—diffuse desmin and progesterone receptor positivity with CD34 and S100 negativity—are atypical for this entity.

Diagnostic / clinical pearl

An atypical immunohistochemical profile does not exclude an NTRK-rearranged spindle cell neoplasm; molecular identification of the fusion can clarify the diagnosis.

Source

PubMed · PMID 41217387

Published in Int J Gynecol Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.